Osteri 750mcg injection contains the active component Teriparatide. Osteri 750mcg injection, a synthetic version of parathyroid hormone (PTH) produced by the parathyroid glands, is employed for treating osteoporosis. Osteoporosis is a condition marked by weakened bones, heightening the likelihood of fractures. Fractures caused by osteoporosis can severely affect an individual's quality of life, causing pain and restricting mobility. Osteri 750mcg injection functions by promoting the creation of new bone tissue and enhancing bone mineral density. This medication has been shown to accelerate bone healing in individuals with fractures. It promotes the formation of callus, the initial bridge of new bone that forms during the healing process, leading to faster and more efficient recovery. Individuals who have a known hypersensitivity or allergic reaction to the Osteri 750mcg injection or any of its components should not use this medication. It is contraindicated in individuals with a history of skeletal malignancies, such as osteosarcoma, or those with bone metastases. If an individual has received prior radiation therapy involving the skeleton, the use of this medication is not advised due to the potential risk of osteosarcoma development.